XATRAL

This brand name is authorized in Australia, Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Netherlands, Romania, Singapore, South Africa, Tunisia, Turkey, UK.

Active ingredients

The drug XATRAL contains one active pharmaceutical ingredient (API):

1	Alfuzosin UNII 75046A1XTN - ALFUZOSIN HYDROCHLORIDE
	Alfuzosin is an orally active quinazoline derivative. It is a selective, peripherally acting antagonist of postsynaptic alpha-1-adrenoceptors. In vitro pharmacological studies have documented the selectivity of alfuzosin for the alpha-1-adrenoreceptors located in the prostate, bladder base and prostatic urethra.
	Read more about Alfuzosin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XATRAL XL Prolonged release tablets	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G04CA01	Alfuzosin	G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CA Alpha-adrenoreceptor antagonists
Discover more medicines within G04CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	4277D
BR	Câmara de Regulação do Mercado de Medicamentos	576720090086817
CA	Health Products and Food Branch	02245565
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	29579-1-01-11
EE	Ravimiamet	1011632, 1064247, 1529557, 1529568
FI	Lääkealan turvallisuus- ja kehittämiskeskus	566042, 566075
FR	Base de données publique des médicaments	60443609, 61889938, 62415971, 64068708
GB	Medicines & Healthcare Products Regulatory Agency	139798, 139800, 175984, 31878, 31888
HK	Department of Health Drug Office	41468, 47335
IE	Health Products Regulatory Authority	52613, 52751, 53406, 53572, 53597
IL	מִשְׂרַד הַבְּרִיאוּת	3643, 4360
IT	Agenzia del Farmaco	027314044
LT	Valstybinė vaistų kontrolės tarnyba	1003208, 1003439, 1014150
MT	Medicines Authority	AA908/18301, MA1359/03501, PI1438/02201A, PI908/18302A
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	534M2000
NL	Z-Index G-Standaard, PRK	54798
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W62086002, W62086003
SG	Health Sciences Authority	09546P, 11579P
TN	Direction de la Pharmacie et du Médicament	6453041, 6453043
TR	İlaç ve Tıbbi Cihaz Kurumu	8699809037748
ZA	Health Products Regulatory Authority	35/5.2/0074